Data presented at AAO 2022 demonstrated that monthly and every-other-month (EOM) treatment with pegcetacoplan preserved visual function of retinal cells near the geographic atrophy (GA) lesion border.
In the phase 3 OAKS study of the investigational targeted C3 therapy, patients treated with monthly or EOM pegcetacoplan loss less retinal sensitivity and had fewer new scotomatous points, which measures nonfunctioning areas of the retina, over 24 months with increasing effects over time, compared to patients in the sham group.
“These results provide the first direct evidence that slowing GA lesion growth has the potential to preserve visual function,” said Charles Wykoff, MD, PhD, presenting author and director of research, Retina Consultants of Texas, in an Apellis press release. “There is a pressing need for a treatment for GA given the progressive, irreversible vision loss that severely impacts daily living for millions of patients. Combined, these data underscore the potential of pegcetacoplan to preserve vision over the long term and become the first treatment for GA.”
Reference
Wykoff CC, et al. Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials. Presented at: AAO 2022.
This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.
Related Content
